COMMUNIQUÉS West-GlobeNewswire

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
14/08/2026
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/ [...]
GT Biopharma Reports Second Quarter 2026 Financial Results
14/08/2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 [...]
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
14/08/2026
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients [...]
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
14/08/2026
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to [...]
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
14/08/2026
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD [...]
Indiana Center for Recovery Named No. 1 Addiction Treatment Center in Indiana by Newsweek
14/08/2026
Indiana Center for Recovery in Bloomington ranks top in the state on Newsweek’s 2026 list for excellence in addiction treatment and mental health services. BLOOMINGTON, Ind., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Indiana [...]
Milestone Scientific Reports Financial Results for Second Quarter 2026
14/08/2026
Medical Segment Revenue Grows 231% Year-Over-Year Enters Strategic Distribution Agreement to Expand CompuFlo® Access Across VA and Department of Defense Health Systems Reaffirms 2026 Outlook for Double-Digit Revenue [...]
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
14/08/2026
- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“ [...]
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
14/08/2026
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 [...]
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
14/08/2026
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including [...]
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
14/08/2026
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway [...]
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
14/08/2026
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference New clinical data for bizaxofusp, used for the treatment of unresectable recurrent IDH-WT [...]
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
14/08/2026
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations Announced [...]
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in [...]
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
14/08/2026
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed [...]
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
14/08/2026
Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026 Successfully completed [...]
ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system
14/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX ® ) and house dust mite tablet ( [...]
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14/08/2026
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced [...]
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
14/08/2026
Cette soumission repose sur les résultats positifs d’efficacité et de sécurité de l’étude de Phase 3 VALOR NEW YORK & LYON, France, le 14 août 2026, Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext [...]

Pages